Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally

Clinical Trial Description

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer (TNBC) ;

Study Design

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04879849` - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers	Phase 1
Recruiting	`NCT06057636` - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study	N/A
Withdrawn	`NCT02427581` - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 1
Completed	`NCT02789332` - Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency	Phase 2
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1
Recruiting	`NCT05208762` - A Study of SGN-PDL1V in Advanced Solid Tumors	Phase 1
Completed	`NCT01969643` - A Safety Study of SGN-LIV1A in Breast Cancer Patients	Phase 1
Terminated	`NCT04489940` - Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer	Phase 2
Not yet recruiting	`NCT06154109` - Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial	Phase 2
Withdrawn	`NCT02539017` - The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer	Phase 2
Terminated	`NCT02720185` - Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR	Phase 2
Completed	`NCT03092934` - A Study of AK-01 (LY3295668) in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04895709` - A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03036488` - Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)	Phase 3
Recruiting	`NCT05252390` - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT02685306` - A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer	Phase 2
Active, not recruiting	`NCT04251533` - Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss	Phase 3
Recruiting	`NCT05435352` - Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment
Active, not recruiting	`NCT02926196` - Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab	Phase 3

NCT number	NCT03997123
Study type	Interventional
Source	AstraZeneca
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 25, 2019
Completion date	March 18, 2024

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC — CAPItello-290

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms